IFOM
  1. Home
  2. Research
  3. Researchers
  4. Chiara Ambrogio

Chiara Ambrogio

In addition to leading her laboratory at IFOM, Chiara Ambrogio, PhD, is Full Professor of Molecular Biology at the University of Torino and Principal Investigator at the Molecular Biotechnology Center (MBC), where she leads a research program focused on oncogenic signaling and targeted therapies in cancer. Chiara Ambrogio received her degree in Medical Biotechnology and her PhD in Immunology and Cell Biology from the University of Torino. She completed her postdoctoral training at the Spanish National Cancer Research Center (CNIO) in Madrid under the supervision of Mariano Barbacid and later at the Dana-Farber Cancer Institute, Harvard Medical School in Boston, where she worked as Senior Scientist in the laboratory of Pasi Jänne, gaining extensive expertise in translational oncology and lung cancer research. In 2019, supported by a prestigious Armenise-Harvard Foundation Career Development Award, she established her independent laboratory in Torino. Her work has significantly contributed to understanding RAS-driven cancers and mechanisms of drug resistance, with publications in leading international journals. She is an active member of major scientific societies, serves on international advisory boards, and is regularly invited as a speaker at major conferences in molecular oncology and precision medicine.

Key Scientific Achievements

  • ERC Consolidator Grant (2021–2027) – Molecular and biological dynamics of the KRAS signalosome
  • ERC Proof of Concept Grant (2025–2026) – translational development of oncology strategies
  • Harvard-Armenise Career Development Award
  • Lung Cancer Research Foundation (LCRF) Scientific Merit Award
  • Editorial Board Member: Molecular Cancer Research, British Journal of Cancer
  • Board Member, European Association for Cancer Research (EACR)
  • Scientific Advisory Board Member, Lung Cancer Research Foundation (LCRF)
  • Reviewer for major funding agencies (CRUK, MRC, Wellcome Trust, ERC-related panels)
  • Invited speaker at major international conferences (AACR, EACR, ESMO, IASLC)

Research Focus

The research of Chiara Ambrogio focuses on RAS oncogenes, targeted therapy and drug resistance in cancer. Her work aims to understand how oncogenic signaling networks drive tumor initiation and adaptation to therapy, with particular emphasis on molecular signaling rewiring and tumor evolution. By integrating in vivo RAS-driven cancer models with multi-omics approaches, her research defines mechanisms of resistance and identifies actionable vulnerabilities that can be exploited therapeutically. A central goal is to develop predictive frameworks for treatment strategies and improve clinical outcomes for patients with RAS-driven cancers.

Scientific productivity

Chiara Ambrogio has an H-index of 42 and has authored publications in leading international journals, including Cell, Nature Medicine and Nature. Her work spans fundamental cancer biology and translational oncology, with a strong focus on RAS signaling and therapeutic resistance. She regularly publishes in top-tier journals and contributes to high-impact collaborative studies. Full publication metrics and updated records are available on her Google Scholar profile ORCID: 0000-0003-4122-701X

Ambrogio Lab Ambrogio Lab Research program Publications (Google Scholar) Contact the researcher
Chiara Ambrogio, PhD, is Full Professor of Molecular Biology at the University of Torino and Principal Investigator at the Molecular Biotechnology Center (MBC)